Nanomerics

Nanomerics is a speciality pharmaceutical company which was spun out from University College London. Nanomerics creates differentiated medicines based on its patented Molecular Envelope Technology (MET).

membership
Organisation type
Prof Ijeoma Uchegbu
Chief Scientific Officer 

Phastar

PHASTAR is a specialist CRO offering statistical consultancy, clinical trial reporting (including data management) and medical writing services, by providing expert consultants and delivering in-house projects.

Every project PHASTAR undertakes is supervised on methodology and utilises internal processes designed to ensure optimal quality. We are headquartered in London with 7 offices globally across four continents, and the largest statistical CRO group in Europe.

membership
Organisation type
Mr Kevin Kane
CEO 

Richmond Pharmacology Limited

Based at St Georges University of London, Richmond Pharmacology Limited is one of 14 MHRA accredited UK phase one units specialising in early phase Adaptive Studies (including First-In-Human), Cardiac Safety/Intensive ECG/Thorough QT studies, Ethnic Bridging studies and Patient Studies.

Our Principal Investigators offer peer-to-peer advice, intelligent protocol design and development and expert know-how for global regulatory requirements.Our streamlined methods ensure we deliver each milestone right on cue, with no extensions and no extra cost.

Dr Jörg Täubel
CEO 

SCIAD

Sciad Communications is a leading marketing and PR consultancy working in Health, Science and Tech.Our aim is to make our clients more successful. By integrating Brand, PR and Digital Marketing we build reputations, accelerate growth and attract investment. We have an excellent track record in developing communications programmes for our clients, helping them to stay ahead of their competitors and become market leaders.

membership
Organisation type
Ms Deborah Cockerill
Managing Partner and Co-Founder 

Scottish Development International

Scottish Development International is a government-funded organisation which provides access to key Scottish product and service companies in the life sciences, together with research and clinical expertise from Scottish Universities and Research Institutes and financial support programs to support your development.

Scotland’s life sciences sector consists of over 650 organisations employing over 32,500 people and is one of the world's leading centres for stem cell research and regenerative medicine. Scotland has built a reputation as one of Europe's leading locations for the development of new tools and technologies, as well as the clinical assessment of new cell-based therapies. These strengths are based on the connectivity of the translational, clinical, analytical and regulatory support mechanisms.

Mrs Emily Lekkas
International Senior Executive 
Ms Katharina Kraehahn
Senior Business Development Executive 

Seven Bridges

Seven Bridges is the biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development and precision medicine. The scalable, cloud-based Seven Bridges Platform empowers rapid, collaborative analysis of millions of genomes in concert with other forms of biomedical data. Thousands of researchers in government, biotech, pharmaceutical and academic labs use Seven Bridges, including three of the largest genomics projects in the world: U.S. National Cancer Institute’s Cancer Genomics Cloud pilot, the Million Veteran Program and Genomics England’s 100,000 Genomes Project. As the NIH’s only commercial Trusted Partner, Seven Bridges authenticates and authorizes access to one of the world’s largest cancer genomics dataset. The company has offices in Cambridge, Mass.; Belgrade; London and San Francisco.

Mr Michael Reynolds
Senior Account Director 

SiSaf Ltd

SiSaf is a Specialty Biopharmaceutical company with a unique patented next-generation Bio-adoptive silicon technology that can elegantly re-invent and solve even the most complex drug and bio-availability challenges.

Website:
www.sisaf.co.uk
membership
Organisation type
Dr Michael Welsh
Chief Scientific Officer 

Strategy in Life Sciences

Strategy in Life Sciences (SiLS) is a strategy consulting firm focused on the needs of the life sciences sector. We work with organisations to improve their performance, drive high quality decision making and develop winning strategies.

We work on issues from R&D portfolio management to commercial strategy, underpinned by our knowledge of the industry, strategy development and underlying science. Our experience includes working with companies and organisations across the world.

Dr Andrew Bell
Managing Director 

Tecrea Ltd

Tecrea Ltd is a UK based Biotechnology Company focused on nanotechnology as a means of creating novel drug formulations to treat serious medical conditions in human and animal health. Our Nanocin™ nanotechnology platform has already been partnered in both human and animal health. Commercial traction has been achieved with sales and out-licensing to bioprocessing and pharmaceutical companies, with one of our partners entering phase II clinical development early in 2017.

membership
Organisation type
Dr John Ridden
Director 

The Research Network

TRN are an integrated team of scientific experts who provide Pharmaceutical R&D scientific consultancy, project management, outsourcing and due diligence services. Our experienced team has in depth expertise across the key drug discovery and development disciplines covering both small molecule and biotherapeutics.

TRN also collaborate with Universities and research organisations to progress promising drug discovery projects from lead identification through early clinical development. We partner with Principal Investigators and Technology Transfer groups to secure funding, provide strategic guidance and practical support to access and manage available technologies and resources worldwide. Much of this work is conducted at risk. Areas of focus are acute care, antibiotics, antivirals, neurodegeneration and CVMD.

TRN are currently working in collaboration with the University of Tennessee and the MRCT to enable the development of EmstoPA, a humanised antibody fragment for the treatment of bleeding complications in patients who have received the clot buster tPA, for the treatment of stroke or pulmonary embolism. Currently no specific tPA reversal agents are in development. The team are seeking investors to help fund the development of this exciting and innovative product. Two additional drug repurposing collaborations are in early development in the acute care arena.

Website:
http://trn.net/
membership
Organisation type
Dr Charles Phillips
Network Partner, Regulatory Team Lead